Loading...
Please wait, while we are loading the content...
Similar Documents
Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes
| Content Provider | Scilit |
|---|---|
| Author | O'Brien, Susan Jain, Preetesh Kantarjian, Hagop Sasaki, Koji Jabbour, Elias Dasarathula, Jyothsna Gonzalez, Graciela Nogueras Verstovsek, Srdan Borthakur, Gautam Wierda, William Kadia, Tapan Dellasala, Sara Pierce, Sherry Ravandi, Farhad Cortes, Jorge |
| Copyright Year | 2016 |
| Description | Journal: British Journal of Haematology This study assessed the relevance of 2013 European LeukaemiaNet (ELN) response categories on patients treated with common frontline tyrosine kinase inhibitors (TKI) in chronic myeloid leukaemia in chronic phase (CML-CP). Four hundred and eighty-seven patients treated with imatinib (400 mg; IM 400, n = 70; 800 mg; IM800, n = 201), dasatinib (n = 107) or nilotinib (n = 109) were analysed. Intention to treat (ITT) analysis indicated that the proportion of patients falling into optimal, warning and failure ELN categories were 89%, 6%, 6% at 3 months, 78%, 17% and 6% at 6 months, and 75%, 13% and 13% at 12 months, respectively. Rates of optimal response at 3 months were 75% for IM400, 90% for IM800, 89% for dasatinib and 97% for nilotinib; 41%, 80%, 86% and 89% at 6 months; and 47%, 77%, 76% and 87% at 12 months, respectively. Patients achieving optimal response had longer eventfree (EFS), failurefree (FFS), transformationfree (TFS) and overall survival (OS) compared to warning and failure responses at all-time points. Treatment with imatinib 800, dasatinib or nilotinib predicted for achieving an optimal response. Optimal response predicted for significantly longer EFS, FFS, TFS and OS at 3, 6 and 12 months, irrespective of the TKI modality used. ELN response categories reliably predicted outcomes in CML patients receiving commonly used TKIs. |
| Related Links | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4809772/pdf |
| Ending Page | 126 |
| Page Count | 13 |
| Starting Page | 114 |
| e-ISSN | 13652141 |
| DOI | 10.1111/bjh.13936 |
| Journal | British Journal of Haematology |
| Issue Number | 1 |
| Volume Number | 173 |
| Language | English |
| Publisher | Wiley-Blackwell |
| Publisher Date | 2016-02-05 |
| Access Restriction | Open |
| Subject Keyword | Journal: British Journal of Haematology European Leukaemianet Chronic Myeloid Leukaemia Response in Cml Tyrosine Kinase Inhibitor (tki) |
| Content Type | Text |
| Resource Type | Article |
